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ABSTRACT
The Molecular Mechanism of Migraine
Kristin Watson Nilsen
Department of Chemistry and Biochemistry, BYU
Master of Science
Migraine is a common, episodic neurological disorder that includes headache, nausea and
hypersensitivity to sensory stimuli. During the headache phase of migraine, migraine patients can
be especially hypersensitive to thermal stimuli. The unpredictable and episodic nature of
migraine makes it difficult to treat and much of the mechanism of migraine has yet to be
elucidated. A T44A substitution in casein kinase 1δ is inherited with migraine with aura. A
transgenic mouse model suggests that animals with this mutation exhibit increased sensitivity to
thermal stimuli after injection with nitroglycerin (NTG). We performed behavior assays that
measure animal responses to thermal stimuli, after injection with NTG, a known migraineinducer in human migraine patients. Female animals with the CK1δ-T44A mutation are more
sensitive than wildtype littermates, suggesting a sex difference emerges in pain sensitivity in
animals that express the CK1δ-T44A but not in wildtype siblings. Female CK1δ-T44A animals
are more sensitive to the effects of NTG on pain than male CK1δ-T44A mice. This indicates a
potential sex hormone related pain response. Since estrogen is implicated in both migraine and
pain response, we test the thermal sensitivity of heterozygous ERβKO/+ and CK1δ-T44A;
ERβKO/+ mice compared to wildtype and CK1δ-T44A mice. Overall thermal sensitivity is
decreased before stress of injection in both male and female ERβKO/+ and CK1δ-T44A: ERβKO/+
mice. This demonstrates that ERβ is necessary for thermal nociception in untreated mice.
However, after injection with saline or NTG, animals of all genotypes responded to thermal
stimuli similarly. This suggests that estrogen signaling through ERβ is likely not part of the
pathway of NTG-induced thermal sensitivity or that one copy of ERβ is sufficient for NTGinduced thermal sensitivity. Since ERβ is fully functional in CK1δ-T44A mice and CK1δ-T44A
mice have wildtype thermal sensitivity at baseline, we can conclude that CK1δ-T44A does not
modulate ERβ to affect thermal sensitivity in untreated animals.
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CHAPTER 1: INTRODUCTION

General Information
Migraine is a common neurological disorder that can be completely disabling. Migraines
are characterized by recurrent episodes that may include headache localized to one cerebral
hemisphere, moderate to severe pain intensity, pulsing, nausea, and sensitivity to light, sound,
touch, heat or smell3.
Another symptom of migraine is aura, a disturbance characterized by a scatoma that
moves across the visual field. In addition to the visual disturbance, aura can also affect speech
and motor function3a, 4. This type of migraine is called migraine with aura (MA). A subtype of
MA is familial hemiplegic migraine (FHM), which is dominantly inherited and paralysis of half
of the body as the aura occurs. Other variants of MA include migraine with prolonged aura and
migrainous stroke3a. Migraine is also associated with several other disorders including
hypomania, depression, anxiety, phobia, panic disorder, stroke, familial dyslipoproteinenmias,
essential tremor, paroxysmal dyskinesias, and epilepsy3a.
Another characteristic of migraine is that it is episodic and therefore difficult to
accurately predict. However, some migraine patients can identify an environmental trigger.
These include bright lights, caffeine, alcohol, strong odors, cheese, chocolate, stress, and changes
in sleeping patterns or hormone levels5. While these triggers increase risk to a pre-disposed
person, they do not always elicit a migraine response, are not universal, and can change
throughout the course of a lifetime within the same person.
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Models of Migraine
The unpredictability of migraine makes it difficult to study. To overcome this obstacle,
chemicals that elicit some of the traits of migraine have been used to create models to study
migraine in both animals and human migraine patients. These models include nitroglycerininduced hypersensitivity, cortical spreading depression, and meningeal inflammation. For human
patients, some migraine attacks have been recorded using functional magnetic resonance
imaging.

Nitroglycerin
The hypertension and angina medication nitroglycerin (NTG) can induce migraine in
patients pre-disposed to migraine6. NTG-induced migraine can induce aura in patients with
histories of aura, and it is likely the NTG headache is the result of both vasodilatation in cranial
blood vessels and stimulation of dural afferents6b,7. NTG can also induce hypersensitivity to
sensory stimuli including touch and heat in migraine patients8. Thus, NTG provides a way to
induce a migraine-like attack in pre-disposed persons in a controlled manner, which is useful for
studying migraine.
NTG has also been used as a model to trigger migraine in animal studies. In rats, NTG, a
NO donor, has been shown to increase spinal responses in afferent neurons, sensitize the
trigeminal afferents that innervate the dura, and increase response to pain9. NTG also induces
FOS expression in the trigeminal nucleus caudalis10, which is suppressed by the anti-migraine
drug Eletripan11. In mice, NTG induced a dose-dependent and prolonged allodynic response to
both thermal and mechanical stimuli. It also increased FOS expression in the trigeminal nucleus
caudalis and cervical spinal cord dorsal horn6b. A recent study showed that NTG induces thermal
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hypersensitivity in mice at both 5 and 10mg/kg doses, which developed within 30 minutes of
injection, peaked at 60 minutes and abated after 4 hours6b. NTG also induced mechanical
hypersensitivity with the von Frey mechanical-sensitivity assay at 10mg/kg 60 minutes after
injection, which subsided after 4 hours6b. The anti-migraine drug Sumatriptan provided relief of
induced allyodynia in both cases. Another study showed pain behavior in rats after NTG
injection. A significant reduction in the latency of the tail-flick assay and increase in formalininduced pain-related behavior at 2 and 4 hours after NTG administration was observed9e. NTG
was not shown however, to lower the threshold for cortical spreading depression (CSD), a
measure of cortical excitability, suggesting that NTG acts downstream or acts independently of
CSD6b. The pain-induced behaviors exhibited by both rats and mice in previous studies show that
NTG provides a useful method to model migraine in animals.

Cortical Spreading Depression
Cortical Spreading Depression (CSD) is a wave of spreading depolarization followed by
a wave of inactivity in the cortex that can be caused by chemical, physical, or electrical
disturbances12. In response to a stimulus, a self-propagating wave of neuron depolarization
spreads across the cortex12a. This spreading depression of neural activity parallels the path of
aura12b. These changes in neuronal impulses measured in the cortex of animals maybe the
equivalent to the human aura13. Arterial dilation precedes the CSD wavefront. Mice expressing
alleles associated with familial hemiplegic migraine type 1 show a reduced threshold for
induction of CSD14 as well as faster propagation of CSD15. The threshold stimuli required to
induce CSD, the frequency of occurrence, and the rate of neuronal recovery are parameters of
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CSD that can be compared between animal models of migraine. Medications that have been
effective at preventing migraine affect threshold and frequency of CSD induction14-16.

Meningeal Inflammation
Meningeal neurogenic inflammation results from the activation of the trigeminal neurons
that are also activated during migraine17. Chemical stimulation via inflammatory factors, lowosmotic buffer, or ionic salts causes sensitization of the dural afferents in the trigeminal
ganglion12b. This sensitization can be exacerbated by mechanical stimuli. The release of
neuropeptides from the dural afferents results in plasma protein extravasations, vasodilatation,
degranulation of mast cells and subsequent release of serotonin, histamine, and cytokines12b, 17.
These substances are pro-inflammatory and produce dural sensitization, causing normally
painless motions such as sudden head moving, coughing, or breath-holding to significantly
worsen already existing head pain12b. One study showed that chemical stimulation of rat dural
receptive fields directly excited the neurons and increased the mechanical sensitivity of the rat to
previously innocuous stimuli12b. The chemical sensitivity and sensitization characteristics of
afferents may contribute to intracranial mechanical hypersensitivity, which is common in certain
forms of headache and could contribute to the throbbing pain of migraine12b.

Functional Magnetic Resonance Imaging
Functional magnetic resonance imaging (fMRI) allows the visualization of the soft
tissues and the flow of blood in the brain18. When a neuron is activated it requires more oxygen
and blood flow to the region of activity. This increase in blood flow occurs 1-5 seconds after

4

neuron excitability and also alters local blood volume levels18a, b. Both blood flow changes and
blood volume changes can be measured with fMRI. Arterial dilation precedes the CSD
wavefront but abates during the spreading depolarization stage. One study showed cerebral blood
flow and volume decreased during migraine aura and move at the same rate as CSD19. These
decreases also abated after the aura was finished, indicating that non-severe ischemia was
spreading over the cerebral cortex19.

Genetic Factors
Many genetic factors contribute to the migraine phenotype. One type of inherited
migraine is familial hemiplegic migraine (FHM), a rare form of migraine affecting about 1% of
migraine patients. FHM can be caused by mutations in the CACNA1A (calcium channel),
ATP1A2 (sodium/potassium ATPase), and SCN1A (sodium channel) ion channels20. Other
single nucleotide polymorphisms, rs1835740 and KCNK18, have been linked to the more
common migraine with aura subtype but are only correlative and do not have a definitive
causative connection or molecular mechanism established.

Familial Hemiplegic Migraine (FHM)
Mutations in CACNA1A (calcium channel), ATP1A2 (sodium/potassium ATPase), and
SCN1A (sodium channel) have been found to be causative for FHM20. CACNA1A is a voltagegated calcium channel23, 15, 21. Calcium channels are composed of multiple-subunits: α1, β, α2δ22.
Subunit α1 is a transmembrane protein, which acts as a voltage sensor and forms the ionconducting pore in the membrane23. FHM is caused by missense mutations in the α1a subunit of
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the calcium channel gene (CACNA1A)23, 15, 21. In cultured neurons, the mutations in CACNA1A
cause a negative shift in voltage dependence and delay in channel inactivation 15. This causes the
channels to respond to smaller depolarizations and stay open longer, enabling more calcium into
presynaptic terminals15, 24. The increase in calcium leads to increased excitatory
neurotransmission15 as shown in one study with mice having the CACNA1A mutation24. Studies
have shown that mice with CACNA1A mutations exhibit a phenotype of increased susceptibility,
frequency, and propagation speed of CSD, a physiological correlate of aura15-16. Female mutant
mice have a greater propensity than male mice to CSD14. One study showed this susceptibility
diminished after ovariectomy, but could be partially restored with estrogen supplements15-16.
Electrical stimulation thresholds for wildtype and mutant female mice are 50% less than that of
males16. Eikermann-Haerter also showed that CSD propensity could be increased in mutant
males via orchiectomy, indicating a possible role for androgens in the suppression of migraine15.
Missense mutations in the ATP1A2 gene, which encodes the NA,K-ATPase α2 subunit,
have also been identified in FHM . These mutation result in reduced activity25 or decreased
affinity for K+26 of the Na+ /K+ pump and impair uptake of K+ from the extracellular space27.
One specific missense mutation in the NA,K-ATPase channel is the T345A substitution, which
was identified in a Finnish family with FHM26. In rats, this mutation did not alter cell growth or
catalytic turnover but it did cause a significant decrease in apparent K+ affinity. This affinity is
the basis for a reduced rate of K+ uptake, which delays the recovery phase of nerve impulses
important in FHM26.
Another FHM-linked mutation was discovered when sequencing chromosome 2q24. The
sequencing revealed a heterozygous missense mutation in the neuronal voltage-gated Na+
channel gene SCN1A. The GLN1489Lys mutation was present in three different families with
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FHM and resulted in a charge-altering amino acid exchange in the hinged-lid domain28. This
affects the fast inactivation of the channel which is located in cortical neurons29 and is essential
for the generation and propagation of action potentials in the brain. Whole cell recordings of
Na+ currents in cells expressing the highly homologous SCN5A sodium channel showed the
mutation induced a 2-4 fold accelerated recovery from fast inactivation. This means it allows
higher firing rates and thus, enhance excitability in the neuronal network, which contributes to
migraine28.

Migraine Genes
A genome-wide association study of migraine found that in 95 % of 2731 migraine cases
a single nucleotide polymorphism in the minor allele of rs1835740 on chromosome 8q22.1 was
associated with migraine30. This single nucleotide polymorphism is located between the genes
encoding astrocyte elevated gene 1 (AEG-1) and plasma glutamate carboxypeptidase (PGCP),
indicating a connection to glutamate signaling. This connecting region could regulate one or both
of these genes. AEG-1 downregulates SLCA2, a gene that encodes the major glutamate
transporter in the brain, while increased glutamate in the synaptic cleft or downregulation of
SLC1A2 increases PGCP activity. Since glutamate is a major neurotransmitter in the brain, this
increased amount of glutamate could lead to neuronal hyperexcitability, and is likely to increase
the occurrence of migraine because of enhanced sensitivity to CSD and central sensitization30.
In a family with dominantly-inherited migraine with aura, a frame shift mutation in the
gene, KCNK18, was found to segregate with the migraine trait. KCNK18 encodes TRESK, a
TWIK-related spinal cord potassium channel previously implicated in pain pathways and
anesthesia31. TRESK is expressed in the trigeminal ganglion where neurons are activated during

7

migraine. The mutation results in a complete loss of function of the ion channel, which also
dominantly-negatively suppresses wild-type channel function, leading to migraine pathology31.
However, studies have only shown these two genes to be correlative with migraine and have yet
to establish causative evidence or possible mechanism for migraine incident.

Casein kinase 1δ (CK1δ)
Casein kinase 1δ (CK1δ) is the first gene to have been shown to have a causative link to
migraine with aura. A recent study identified a novel mutation in a family with dominantlyinherited migraine with aura. The family was also diagnosed with familial advanced phase
syndrome (FASPS), a circadian disorder32. Upon being screened for genes linked to this
disorder, a mutation in CK1δ was identified in those family members affected with migraine
with aura. A T44A substitution in the protein encoded by this gene segregates with a circadian
phenotype and migraine with aura20. CK1δ phosphorylates Per2, another constituent of the
circadian clock whose phosphorylated state modulates the rate of its degradation33. The T44A
substitution is not in the active site or the activation domain of CK1δ, so it is likely the mutations
affects the protein’s interactions with other proteins32. The mutant kinase showed reduced
function in vitro for phosphorylation of Per1, Per2, Per3 and α-casein. Mouse and fly models
expressing the mutant allele exhibit abnormal circadian phenotypes32. Transgenic mice with this
mutation exhibited behaviors characteristic of migraine with aura. Thresholds to induce aura can
be measured through CSD and vascular changes. Sensitivity to mechanical and thermal stimuli is
also another method of identifying migraine in mouse models. Together, pain behavior assays
and changes in CSD thresholds with associated vascular dynamics demonstrated that CK1δ is
causative for migraine with aura20. The target of CK1δ that is causative for migraine is unknown
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since it is a ubiquitous and promiscuous kinase. CK1δ phosphorylates many targets that could be
involved in migraine such as connexins that form gap junctions, NMDA receptors, glutamate
signaling proteins, and estrogen receptors20.

CK1δ Regulates Gap Junctions
In the brain, the wave of CDS that mirrors aura during migraine propagates via the gap
junctions that connect cells. Gap junctions are membrane channels that allow direct
communication through electrical, biochemical, or metabolic interaction between adjacent
eukaryotic cells61, 62, 63, 34, 65, 35. Gap junctions are channels made up of two hemi-channels, each
composed of six connexin proteins65,35b. These channels allow the diffusion of nutrients, wastes,
metabolites, second messengers, and ions between cells65,35b. CK1δ regulates formation of gap
junctions. Phosphorylation of connexin-43 (Cx43) is necessary for gap junction assembly and
CK1δ phosphorylates Cx43 serines 325, 328, or 33036. A general CK1 inhibitor decreased
phosphorylation of Cx43 at these sites36. Upon the addition of a CK1δ-specific inhibitor, a
decrease in both gap junction formation and Cx43 phosphorylation occurred in cells. CK1δ was
inhibited and connexin-43 was localized at plasma membranes and not cell junctions36. The
mechanism of this interaction has not yet been completely determined, but these data indicate
that CK1δ is responsible for phosphorylation of connexin-43 and subsequent gap junction
formation36, which are important in the progress of migraine.
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CK1 Regulates Synaptic Transmission
Migraines propagate through the brain via excitation of neurons, or fast synaptic
transmission, which occur when neurons are stimulated by neurotransmitters such as glutamate.
CK1 has been shown to regulate fast synaptic transmission. The glutamate receptor mGluR1
uses CK1 to inhibit NMDA-mediated synaptic currents. A recent study showed that CK1
decreased NMDA receptor activity in the striatum by increasing phosphatase 1 and/or 2A
activity, which subsequently dephosphorylated NMDA receptors. This is the first evidence of
CK1 regulation of synaptic regulation in the brain37 and is potentially important in migraine
since aura is thought to mirror the neuronal depolarization wave of CSD. Migraine patients
experiencing aura have delayed synaptic recovery, which could potentially be related to CK1regulated NMDA inhibition.

Estrogen
CK1δ has been shown to phosphorylate estrogen receptor α (ERα) directly and via the
AIB1 protein38, indicating a link between CK1δ and estrogen receptors.
Estrogen is part of a group of steroid
compounds that diffuse readily across the
cell membrane into the cytoplasm.
Estrogen has many functions in the central
nervous system and many of these are
modulated by intracellular
receptor/transcription factors that interact

Figure 1: Free estrogen binds to estrogen receptors (α), which
then dimerize and translocate to the nucleus to regulate
gene expression.
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with steroid response elements on specific genes39. As shown in Figure 1, estrogen binds an
estrogen receptor (ER), where it translocates to the nucleus. Activated ERs dimerize and bind to
DNA to regulate gene expression. ERs are part of the nuclear receptor (NR) superfamily and are
transcriptional factors that recruit transcriptional machinery to upregulate gene expression12.
There are at least two types of ERs, alpha (α) and beta (β). Though homology and mode of action
are similar, ERα and ERβ are expressed in a variety of different cells. ERα is expressed
predominately in endometrial, ovarian stroma, hypothalamus and breast cancer cells. And ERβ
is located in kidney, bone, heart, lungs, intestinal mucosa, endothelial and most relevantly, brain
cells49, 40. Estrogen has many effects on brain function including gap junction formation,
serotonin fluctuation, and trigeminal vasodilatation indicating a potential connection with
migraine.

Estrogen and Gap Junctions
Estrogen plays a role in gap junction formation. The expression and regulation of
connexin proteins, which make up gap junctions, are controlled by a number of factors including,
neurotransmitters, growth factors, protein kinases, and steroid hormones, such as estrogen61.
Cx43 is an important estrogen-regulated gap junction protein and is most prevalent in
hypothalamic and uterine tissue61, 65, 68. Estrogen and progesterone are released by hypothalamic
stimulation and these hormones then act on the hypothalamus to regulate reproductive
behavior61, 41, such as estrus cycling and sexual behavior in rats and mice61.
High levels of estrogen and progesterone, like those during pregnancy, increase both
connexin expression and gap-junction quantity in the hypothalamus in female rats42. This
increase in the quantity of gap junctions and Cx43, causes an increase in hypothalamic
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stimulation61. One study showed female rats treated with estrogen, progesterone, or both,
increased Cx43 levels in the preoptic area (POA), while estrogen and progesterone decreased
Cx43 in the POA of male rats61. Estrogen plays important roles in gap junction and Cx43
formation in the brain and this could have implications in migraine due to a correlation of aura
with CSD. The delay of CSD recovery in migraine with aura patients might correlate to the
number or efficiency of gap junctions and connexins in the brain. Since estrogen regulates gap
junctions in the brain, it is likely the occurrence of certain migraines could be due to changes in
estrogen signaling.

Gap junction and estrogen are also linked because gap junctions affect regulation of the
estrous cycle, uterine stromal cell communication, and neovascualrization68. Central control of
reproduction occurs in the hypothalamus, so hormonal regulation of hypothalamic gap junctions
is important in the regulation of reproduction. Female Cx43 knockout mice have abnormal
estrous cycles61. Estrogen and progesterone coordinate the cellular differentiation that enables a
blastocyte to implant in the uterus68, 43. Neovascularization accompanies this differentiation and
is the formation of a vascular network in the stromal bed that supports placenta growth and
therefore early embryo survival68, 44. The communication of gap junctions has a vital role in
neovascularization during pregnancy. One study showed the conditional deletion of Cx43 in
stromal cells of pregnant mice caused a disruption in the formation of new blood vessels in these
cells, which lead to a termination of fetal growth and subsequent miscarriage68.The absence of
Cx43 in mice models and in vitro human cells resulted in aberrant stromal cell differentiation
and a decrease in angiogenic factors, including the vascular endothelial growth factor, which
causes neovacularization68. This indicates an important link between hormone-regulated cell-cell
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communication and the maintenance of the vascular network that supports embryonic growth68.
Estrogen signaling and uterine gap junction regulation with subsequent neovascularization is
important in the study of migraine because it suggests a link to aura. Aura, which is thought to
propagate through cells via gap junctional connections, is also affected by vascularization.

Estrogen and Serotonin
Estrogen is linked to anxiety and depression through the serotonin pathway and
treatments of serotonin decrease anxious behavior52,45. Like migraine, more women than men
experience these disorders though prevalence increases with menopause46. Anxiety and
depression are comorbid with migraine3a and estrogen contribution to migraine can result from
altered serotonin receptor activity47.
Serotonin receptor agonists are the drugs that are most effective for treating migraines.
Triptans, are selective agonists for the serotonin (5-hydroxytryptamine or 5-HT) 1B, 1D and
sometimes 1F receptors48. Serotonin levels have been shown to change during the estrous
cycle49. Tryptophan hydroxylase (TPH-1) is the rate-limiting step in serotonin synthesis. A study
of proestrus, trigeminal ganglion TPH-1 mRNA levels were two-fold greater and TPH-1 protein
levels 1.4 times higher than at diestrus60. However, direct treatment with estrogen did not
increase TPH-1 protein levels or 5HT-1B or 1D receptor number60. Serotonin was present in
trigeminal neurons containing calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide
indicative of pain; in neurons binding IB4, a marker of nonpeptidergic nociceptors; and in
neurons containing 5HT-1B receptors60.
Serotonin levels change during migraine50. Anti-migraine drugs induce the stimulation of
serotonin receptors, which inhibit the release of vasoactive neuropeptides like CGRP, while
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neuronal calcium channels increase the release of serotonin51. Serotonin acts at 5-HT receptors
to increase intracellular calcium by freeing calcium stores and activating a calcium influx
pathway52. For this reason calcium levels increase when triptan drugs are used to alleviate
migraine.
Serotonin release, metabolism, reuptake, and synthesis are regulated by estrogen and
estrogen receptor β52. Studies using the elevated plus maze paradigm showed that diestrous mice
were more anxious than their control counterparts52 and females more anxious than males53.
However, another study reported that ovariectomized mice receiving estrogen treatment had
increased anxiety compared to ovariectomized mice receiving no supplement54. Estrogen
receptor beta knockout (ERβKO/ ERβKO) mice, which lack a functional β estrogen receptor were
more anxious than the wildtype mice52. Knockout mice had lower levels of serotonin in stria
terminalis, preoptic area and hippocampus and dorsal raphe52. Low levels of serotonin are
associated with anxiety and depression and migraines frequently occur concurrently or after
episodes of transient depression, indicating a correlation.

Estrogen and Vasodilatation
Estrogen affects vascular cells and arterial function. The trigeminal neurons innervate
the blood vessels in the intracranial meninges and dural venous sinuses55, and it is thought that
changes in blood vessel diameter underlie the pain in migraine headache. The neuropeptide,
CGRP is a vasodilator that increases blood levels during migraine56. Estrogen rapidly increases
the diameter of arteries in ovariectomized female mice by stimulating the production of nitric
oxide and activation of ERK/MAP kinase and phosphatidylinositol 3-kinase. Mice that were
injected with a nitric oxide inhibitor did not have an increased arterial diameter or increased
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activity of either of these kinases. The same result was found when ERα and ERβ knockout
mice were exposed to estrogen57. Early studies showed stimulation of meningeal and cerebral
blood vessels produced a throbbing pain that was absent when parts of the brain not associated
with blood vessels were stimulated58, indicating a mechanism for pain in migraine.

Migraine and Estrogen
Hormonal changes are one of the many triggers of migraines and estrogen in particular
has been linked to migraine3b, 59. Migraines affect three times more women than men, increase in
frequency during puberty and pregnancy, and occur less frequently after menopause47a, 49.
Estrogen cycles and levels are some of the key differences between men and women and
both human migraine patients and animal models have shown sex differences in migraine
occurrence and behavior. Prepubertal girls and boys have a 4%
occurrence of migraines60. However,
the lifetime prevalence for women is
18% and only 6% for men. For 80%
of women, onset of migraine occurs
between ages 10-39 (Figure 2) and
fluctuates greatly due to

Figure 2: The lifetime prevalence of migraine in
women is three times greater than in men 1.

reproductive status and hormonal supplements61.
One animal study showed sex differences exist between male and female wild type mice
in mechanical stimulation and carrageenan-induced inflammation of hind paw, indications of
migraine-like pain. Female mice exhibited a lower paw-withdrawal threshold than male wildtype
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mice. In ERα and ERβ knockout mice, there was no significant difference in the male mice pawwithdrawal thresholds, but female knockouts had higher response thresholds, eliminating the sex
difference seen previously in wildtype mice. Eliminating ERα or ERβ eliminates sex differences
between male and female mice62, suggesting an important role of estrogen in migraine.
Migraine attacks have also been correlated to changes in estrogen levels and specifically
the decline in estradiol level3b, 47a that occurs most dramatically at the beginning of the menstrual
cycle. This is when the onset of migraines is most frequent in women47a.

Menstrual Migraines
Migraines associated with estrogen level fluctuations are termed menstrual migraines.
Two classifications of menstrual migraines have been defined. A pure menstrual migraine is
defined as one that
occurs within 2 days of
the start of the
menstrual cycle and no
other time during the
cycle63. This is when
the level of estrogen
drops the most

Figure 3: Hormone changes through the estrous cycle. The blue line shows the estrogen
levels. The red line is follicle stimulating hormone (FSH) and the green line is
Luteinizing hormone (LH)2.

dramatically (Figure 3). A menstrual-related migraine is one that occurs within in 2 days of the
start of the cycle but occasional attacks occur on other days of the cycle, when estrogen levels
fluctuate63.

16

Correlations between migraine occurrence and estrogen levels during pregnancy and
menopause also provide evidence that estrogen fluctuation may be involved in migraine.
Estrogen levels increase during each trimester of pregnancy and dropped off sharply after
delivery61d, 64. Nearly 80% of migraine patients studied did not have migraines in the third
trimester but 94% of these reported the occurrence of migraines after giving birth61d, 64. Breast
feeding suppresses estrogen level fluctuation and women experience fewer migraines during
lactation65. At menopause, estrogen levels decrease permanently and the occurrence of migraines
also decreases. In a review of 556 menopausal women, 82% reported migraines before
menopause and only 14% reported headache symptoms after menopause66. Thus, the fluctuations
of estrogen levels have a strong correlation to the incidence of migraine.

Estrogen Signaling and Pain
Nociceptors are sensory receptors that respond to potentially damaging stimuli. They are
expressed in the initial cells that signal pain and depend on ion channels in order to facilitate the
transduction of pain67. The pain pathway functions when a noxious stimulus causes
depolarizations, which initiate action potentials from the peripheral sensory system to the
synapse in the central nervous system. Here, the action potentials activate a neurotransmitter
release at the presynaptic terminal67. Understanding the signal pathway of pain is important in
the development of pain therapies. By determining if some ion channels, neuropeptides, growth
factor receptors, or signal transduction cascades are different from other neurons and are unique
in the type of tissue, it could be possible to target specific nociceptors for pain treatment without
targeting other sensory neurons67.
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Estrogen has long been thought to be involved in pain regulation and signaling. Various
studies have shown correlations of estrogen involvement in pain. However, the effects of
estrogen on pain signaling are complex. Studies have shown that estrogen can increase or
decrease pain depending on the type and location of pain68. Acute pain responses seem to be
attenuated by estrogen. Some studies reported longer latencies to acute stimuli in
ovariectomized female animals with hormone regulation as compared to non-hormonal regulated
controls69. Estrogen treatment also decreased the number or intensity of pain responses in
gonadectomized male and female rats70. However, other studies reported estrogen had no affect
on acute pain response36, 69b, 71. Estrogen treatment in women in the early follicular stage, when
estrogen is low, has been shown to result in an increased pain threshold72. Women who
underwent an acute pain assay reported decreased pain perception in the follicular stage, when
estrogen is higher72a. It seems that location plays a role in the effect estrogen has on pain. When
estrogen was located in the peripheral nervous system (PNS), either endogenously or through
replacements, pain was alleviated. Yet, male rats who were injected with estrogen directly into
the central nervous system had increased pain behaviors73. Chronic pain also seems to be
intensified by estrogen. In female rats with arthritis, greater thermal sensitivity occurred in the
proestrous phase of the menstrual cycle, when the estrogen levels are high74. Female animals
also had increased mechanical sensitivity during the proestrous and estrous phases75. Male rats
with spinal cord injury showed an increase in pain response with estrogen modulation76.
Estrogen withdrawal has been linked to migraine because the onset of most menstrual
migraines occurs at the beginning of the estrous cycle, when the estrogen levels sharply
decline47a, 77. Migraine is based on altered neuronal activity and excitability 78. Laser stimulation
can create event potentials in the brain which mimic migraine. The amplitude of these laser-
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evoked potentials (LEPs) is a quantitative index of the neuronal excitability. They decrease
during repeated stimuli showing a progressive decrease in neuronal response77. The decrease in
the amplitude of sensory cortical responses to repeated stimuli to avoid brain overstimulation is
defined as habituation79. In migraine patients between attacks, the LEP amplitudes are normal in
basal conditions, but reduced habituation occurs with repeated stimuli80. During migraine,
migraine patients have increased LEP amplitudes and increased pain perception77, 81. The
effects of estrogen during the pre-menstrual and late luteal phases of the menstrual cycle of
migraine and non-migraine patients showed migraineurs had increased LEP amplitudes and
decreased habituation compared to controls77, but both groups had increased pain sensitivity,
increased amplitude and decreased habituation in the pre-menstrual phase77. This indicates that
estrogen withdrawal may decrease habituation and increase pain perception.

Sumatriptan
Sumatriptan, a type of triptan, which acts on serotonin receptors, is the most commonly
used drug to treat migraine pain82. Animal studies suggest that the effectiveness of Sumatriptan
on migraine pain coincides with the level of the neuropeptide CGRP48, 82-83. In migraines,
activated meningeal nociceptors in the trigeminal ganglion release high levels of CGRP resulting
in vasodilatation and mast cell degranulation, which leads to trigeminal ganglion sensitization84.
Sumatriptan is effective because it causes contraction of cerebral arteries and reduces
neurological inflammation by blocking the release of nociceptors neuropeptides like CGRP82.
This blocking of nociceptors in the pain pathway helps stop sensitization of dural afferents and
alleviates pain82. A study of human migraine patients showed that when Sumatriptan alleviated
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nitroglycerin-induced migraine attack, the plasma CGRP levels were significantly decreased.
However, if the migraine did not improve, CGRP levels were not affected82.
Sumatriptan also alleviates migraine by increasing intracellular calcium levels that act in
the MAPK phosphorylation pathway, which inhibits CGRP expression. The prolonged calcium
increase decreases CGRP promoter activity and subsequently relieves pain 85. Intercellular
calcium fluctuations also control voltage-dependent calcium channels, which regulate
neurotransmitter release and excitability and are important in the incidence of FHM 21, 85a.
While the exact mechanism for migraine remains unclear, many factors indicate the
important role of estrogen. The prevalence of migraine in woman over men and the onset of
migraine sexual dimorphism at puberty, factored with the correlation of both the monthly and
lifetime cycling to migraine, suggest that estrogen may be important in the mechanism of
migraine. Serotonin is also likely part of the migraine pathway. This is suggested by evidence
that serotonin levels change according to estrogen cycling and serotonin mediates estrogencreated anxiety.
Nociceptors rely on ion channels to signal the pain cascade pathway. Specifically,
calcium channels seem to have the most relevance in the migraine pathway. FHM migraine is
the result of mutations in the calcium channel and cellular calcium released after serotonin
receptor stimulation increases serotonin levels that can then free more calcium. This mechanism
is why intracellular calcium levels increase after sumatriptan administration.
Vasodilatation also plays a role in the pain mechanism of migraine. Increases in blood
flow to the brain during migraine are evident from fMRIs. This change in vascular pressure may
be the reason for pain in migraine. Increased levels of CGRP, which is a vasodilator, are also
observed during migraines. Sumatriptan success also parallels CGRP levels. However,
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sensitization of meninges may also contribute partially or entirely to migraine pain. During
migraine, activated meningeal nociceptors release neurotransmitters and signal pain. Estrogen
plays a complex role in pain perception, decreasing acute pain and increasing chronic pain. Low
estrogen also decreases neuronal habituation and increases pain perception.
Gap junctions can be regulated by estrogen signaling and CKIδ activity. During
pregnancy, when high levels of estrogen are present, levels of Cx43 increase. A sexual
dimorphism also occurs when estrogen increases Cx43 levels in female rats but decreases it in
male rats. Cx43 levels are important for proper neovascularization and fetal growth and normal
parturition and may be important in vascularization associated with migraine. The number of gap
junctions in the brain may be related to the delay of cortical spreading depression, a parallel of
aura. Not only does CK1δ phosphorylate gap junction proteins, it also phosphorylates estrogen
receptor α. The research present in the field indicates an intricate pathway for migraine, though
much remains to be elucidated.
We want to determine the effect of the CK1δ-T44A substitution on thermal sensitivity to
heat and if this sensitivity is affected by the gender of the animal. We want to establish if CK1δT44A female mice experience a more pronounced pain difference than the wildtype female and
CK1δ-T44A male mice. We use the Hargreaves pain assay to assess any differences in pain
reaction post NTG injection. We also want to determine the effect of CK1δ on ERβ and if ERβ
heterozygote mice are hypersensitive/hyposensitive compared to wildtype and CK1δ-T44A
mutant mice after NTG injection. We also want to determine if this thermal sensitivity changes
with CK1δ-T44A; ERβko/+ mice.
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CHAPTER 2: THE EFFECTS OF GENDER ON THERMAL SENSITIVITY IN CK1-T44A
AND WILDTYPE MICE

Introduction
A mutant allele of CK1δ-T44A was found to segregate with migraine with aura20. This
mutation leads to increased susceptibility to nitroglycerin-induced mechanical and thermal
hypersensitivity, lower threshold to aura, increased cranial arterial dilation and is causative for
migraine with aura6b.
One study showed CK1δ-T44A male animals responded to lesser mechanical stimuli than
did their wildtype littermates after administration of NTG. The NTG dose required to produce
hypersensitivity to mechanical stimuli in CK1δ-T44A mice was seven times lower than the NTG
dose required to produce a similar effect in controls6b. Similar allodynia responses to NTG have
been noted in human migraine patients8b. Also, a significantly smaller volume of chemical
stimuli was required to elicit CSD in CKIδ-T44A mice compared to wildtype animals, and these
lower CSD thresholds in CK1δ-T44A animals were reproducible. During constant stimulation
over one hour, significantly more CSD events were elicited in CKIδ-T44A mice than in wildtype
mice86.
During CSD, arteries in the cortex change in diameter in both wildtype and CKIδ-T44A
mice. Arteries dilate preceding the CSD wavefront and are followed by a large constriction, a
second large dilation, and a post-CSD dilation. Baseline diameters and second dilatations were
similar for both groups but constriction is less pronounced in CKIδ-T44A than wildtype
arteries6b. Though CK1δ-T44A and wildtype male animals are different in both induction of
CSD and thermal pain thresholds, these studies have not been completed in female mice.
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Correlative evidence suggests a link between migraine occurrence and estrogens signaling
because migraines affect three times more women than men, increase in frequency during
puberty and pregnancy, and occur less frequently after menopause47a, 49. Therefore, we explored
the sex difference in response to thermal stimuli between CK1δ-T44A male and female mice.
We wanted to determine if the same pattern occurs in female CK1δ mutant mice and if these
effects are more severe than in the male mice.

Materials and Methods
Materials: The wildtype mice came from Jackson Labs (Sacramento, CA), the CK1δT44A mice came from the Louis Ptacek lab (UCSF, San Francisco, CA) and the ERβ mice came
from the Jan-Ake Gustafsson lab (Karolinska Institutet, Department of Biosciences and
Nutrition, Sweden). The nitroglycerin (NTG injection, USP 5mg/ml) was from American
Regent, Inc. The saline (0.9% sodium chloride injection, USP) was from Hospir, Inc. The tail
lysis buffer was DirectPCR (Tail) from Viagen. The primers were made in-house on a Mermade
6 (Bioautomation Corporation) DNA synthesizer. The polymerase was GoTaq DNA Polymerase
purchased from Promega. The Hargreaves apparatus was purchased from The University of San
Diego.
Experimental Animals—All experiments were conducted on C57Bl6 wildtype, CK1δT44A, ERβko/+, or CK1δ-T44A; ERβko/+ mice. All genotypes have a C57Bl6 background and
weighed between 18 and 30 grams during experiments. Animals were acclimated to a 12 hour
light-dark cycle and experiments were performed between 8 a.m. and 2 p.m. at 22°C.
Nitroglycerin Administration—A stock of 5 mg/mL nitroglycerin dissolved in 30%
alcohol, 30% propylene glycol, and water was further diluted fresh each day in 0.9% saline.
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Doses of 1, 5, 10 mg/kg were administered Intraperitoneally (IP). Control mice received a dose
of 0.9% saline solution.
Hargreaves Assay—Animals were habituated to the testing apparatus for 60 minutes prior
to determination of baseline nociceptive thresholds. To determine thermal nociceptive
thresholds, the Hargreaves assay focuses radiant heat on the hind paw of each animal and
measures the time in seconds until the mouse removes the hind paw from the source of heat. The
Hargreaves apparatus has a pressure-sensitive plate that turns off the heat source and stops a
timer when the paw is lifted in response to pain. The cut off valve of 20.48 seconds was set to
prevent tissue injury. This timer is accurate to one hundredth of a second. Radiant heat intensity
was set at 5%. Three determinations were averaged for every time point with at least 1 minute
between each trial. Initial measurements were taken as a baseline reference before injection with
saline or NTG. The mice were then with saline or NTG and measurements were taken post
injection at time 90 minutes. The assay was performed by a single researcher who was blind to
both dose and genotype.
Genotyping—Mice were weaned at 25 days, ear marked, and tail clipped for genotyping.
A 0.5cm section was clipped from the end of each animal’s tail. Each tail fragment was lysed
overnight at 55°C in tail lysis buffer and 1 mg/ml of proteinase K solution. The proteinase K
was then inhibited by incubation at 85°C for 45 mins. The crude cell lysate was used in PCR to
identify either CK1δ T44A mutant or ERβ heterozygote mice. To identify the CK1δ-T44A
mutant mice, primers 5’ACACAGTCTGCTGACTGCATCTC and
CTCAGGTCTTTCAAATTCTCATT were used. The program used in the Mastercycler ep
(Eppendorf) cycler was 94°C for 5’, 94°C for 30”, 60°C for 1’, 72°C for 1:30’, 72°C for 7’ and
4°C hold with 35 cycles. The products were subjected to electrophoresis on a 1% agarose gel.
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Lanes with a band at 800 bp show the CK1δ-T44A genotype and lanes without a band
correspond to wildtype animals.
Statistical Analysis—For each paw of each animal, three paw removal measurements
were taken for every time point (baseline and 90 minutes after injection). Heat sensitivity
thresholds from each group of mice treated with equivalent doses of NTG or saline were
averaged. Two-tailed student T-TESTS were performed comparing genotype to genotype, saline
to NTG, and baseline to 90 minutes for all genotypes and genders. p values are given in the text.
Error bars represent SEM. The number of animals tested for each genotype and each dose of
NTG are indicated in the figure legends. Male and female animals are treated as different
genotypes and were separated for all data.

Results
To determine the difference between CK1δ-T44A mutant and wildtype mice in response
to thermal stimuli after NTG injection, we performed a Hargreaves assay for animals of both
genotypes. This experiment measures the animal’s response to a thermal stimulus by determining
latency to animal response to a calibrated heat source. Initial baseline paw withdrawal
measurements of each animal were recorded and withdrawal measurements were again taken 90
minutes after injection with saline and various doses of NTG.
To control for possible stress resulting from injection, both CK1δ-T44A and wildtype
mice received saline injections after baseline responses were recorded (Figure 4). For both
transgenic CK1δ-T44A and wildtype animals, the latency to response after the saline injection
was similarly reduced. At baseline, the transgenic mice responded in an average of 10.01 ± 0.32
(s). Ninety minutes after injection these mice responded at 7.59 ± 0.28 (s). Similarly, the
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wildtype mice responded in an average of 9.64 ± 0.19 (s) at baseline, which decreased to 7.66 ±
0.20 (s) at 90 minutes post injection. The decrease in latency after 90 minutes is significant for
both groups (CK1δ p= 1.05E-5 and wildtype p= 2.70E-12). However, there was no difference in
the latency to response between the CK1δ-T44A mutant and wildtype mice at either baseline or
90 minutes post saline injection. This indicates that the general stress from injection causes a
significant change in sensitivity to heat but this difference is not dependent on CK1δ.

Latency to Response (s)

Saline Female
12
10
8
6

CK1δ-T44A

4

WT

2
0
0

90
Time (min)

Figure 4: The paw-withdrawal response averages to thermal stimuli of CK1δ-T44A and wildtype mice
at baseline and 90 minutes post saline injection. CK1δ-T44A n=13 and wildtype n=26.

To determine if NTG can cause a significant difference in thermal sensitivity between the
CK1δ-T44A mutant and wildtype female mice, both groups were injected with 1, 5 and 10
mg/kg NTG. After receiving a 5 mg/kg dose of NTG, transgenic CK1δ-T44A animals
responded faster to a calibrated heat source than they did at baseline, while wildtype siblings
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remained unaffected by the same dose of NTG (Figure 5). At baseline, before receiving 5 mg/kg
NTG, the CK1δ-T44A mutant mice responded with an average of 10.01 ± 0.0.32 (s), which
decreased to 6.95 ± 0.43 (s) at 90 minutes after injection. The wildtype mice had a paw
withdrawal average of 9.64 ±0.19 (s) at baseline and 9.02 ± 0.37 (s) at 90 minutes post injection.
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Figure 5: The paw-withdrawal response averages to thermal stimuli of CK1δ-T44A and wildtype mice at
baseline and 90 minutes post 5 mg/kg NTG injection. CK1δ-T44A n=14 and wildtype n =26.

While the difference of paw withdrawal response at baseline was not different between the
transgenic and wildtype mice, 90 minutes after injection with 5 mg/kg NTG the female CK1δT44A mice have a much lower latency to response than their female wildtype siblings,
confirmed by a p value of 0.0005. As in human migraine patients, these data show that mice that
express CK1δ-T44A have increased sensitivity to thermal stimuli. At 1mg/kg NTG, the
difference of paw withdrawal response between female CK1δ-T44A and wildtype mice at 90
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minutes post injection was not different (p=0.94). At this dose, CK1δ-T44A mutant mice
responded at baseline with an average of 8.42 ± 0.45 (s), this decreased slightly to 7.31 ± 0.55
(s) at 90 minutes after injection. The wildtype females had a baseline latency to response of 9.55
±0.37 (s), which decreased slightly to 7.27 ± 0.34 (s) at 90 minutes post 1 mg/kg NTG injection.
At 10 mg/kg NTG, the difference between the transgenic and wildtype animals 90 minutes post
injection was also not significant (p= 0.16). Animals that express CK1δ-T44A responded with an
average latency of 8.81 ± 0.52 (s) at baseline, which decreased to 6.75 ±0.45 (s) 90 minutes after
injection of 10mg/kg NTG. Wildtype animals responded with an average latency of 8.99 ± 0.32
(s) at baseline, which decreased to 7.61 ± 0.35 at 90 minutes after injection.
To compare the effect of gender on NTG-induce hypersensitivity, latency to response to a
heat source was compared in female and male CK1δ-T44A mutant and wildtype mice (Figure 6).
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Figure 6: The paw-withdrawal response averages to thermal stimuli of male and female wildtype mice
at baseline and 90 minutes post 5 mg/kg NTG injection. Male n=21 and female n=26.
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At baseline wildtype males had a longer latency to response than wildtype females (p=0.003).
The male wildtype mice had a baseline of 10.49 ± 0.22 (s) and the female mice had a baseline of
9.64 ± 0.19 (s). However, this sex difference disappeared after injection and no difference was
found between male and female wildtype mice 90 minutes post injection with saline or 1, 5, or
10 mg/kg NTG.
To determine the effect of CK1δ-T44A on gender, the latency to thermal response was
compared between transgenic CK1δ-T44A males and females after injection with 5 mg/kg NTG
(Figure 7).
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Figure 7: The paw-withdrawal response averages to thermal stimuli of male and female CK1δ-T44A
mice at baseline and 90 minutes post 5 mg/kg NTG injection. Male n=21 and female n=14.

At 5 mg/kg, the male CK1δ-T44A mice responded slower than CK1δ-T44A female mice at
baseline (p=6.18E-4). Male CK1δ-T44A mice responded in 11.28 ± 0.25 (s), while female CK1δ-
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T44A mice responded to thermal stimuli in 10.01 ± 0.32 (s). Unlike the wildtype mice, this sex
difference is still present after 5 mg/kg NTG injection. Female CK1δ-T44A animals had a
significantly shorter latency to response than the mutant males 90 minutes after injection with
NTG (7.39E-5). The CK1δ-T44A males have a response average of 9.51 ± 0.44 (s), while the
CK1δ-T44A females responded with an average of 6.95 ± 0.43 (s), indicating that CK1δ-T44A
females are more sensitive to thermal stimuli than CK1δ-T44A males after 5 mg/kg NTG. This
sex difference suggests the possible participation of estrogen in NTG-induced sensitivity to
thermal stimuli. No difference occurred at saline, 1 or 10 mg/kg doses.
To determine the affect dose had on both male and female mice, the response to heat at
90 minutes was subtracted from baseline response to thermal stimuli to determine the difference

Difference from Baseline
(s)

Dose Response
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F CK1δ-T44A
F Wildtype
M CK1δ-T44A
M Wildtype

Saline

1

5

10

Dose (mg/kg NTG)
Figure 8: Dose curve for male and female CK1δ-T44A and wildtype animals showing difference from baseline.
Female CK1δ-T44A saline n=14, 1 mg/kg n=7, 5 mg/kg n=14, 10 mg/kg n=3. Male CK1δ-T44A saline
n=21, 1 mg/kg n=6, 5 mg/kg n=21, 10 mg/kg n=4. Female wildtype saline n=25, 1 mg/kg n=7, 5 mg/kg
n=24, 10 mg/kg n=12. Male wildtype saline n=20, 1 mg/kg n=9, 5 mg/kg n=16, 10 mg/kg n=9.
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from baseline of wildtype and CK1δ-T44A mice at 1, 5, and 10 mg/kg NTG and saline. The dose
curve is shown in Figure 8. Female CK1δ-T44A mice had a significant difference from baseline
response compared to wildtype females at 5 mg/kg NTG. Male CK1δ-T44A mice were less
sensitive to heat than wildtype mice at 5 mg/kg. The difference from baseline responses at 1
mg/kg and 10 mg/kg vary widely for both male and female wildtype and CK1δ-T44A mice,
likely because the number of animals at these doses is small.

Discussion
CK1δ-T44A female mice are more sensitive to thermal stimuli than wildtype females
after injection with NTG at a 5 mg/kg dose. This finding is significant since human migraine
patients are more sensitive to heat during migraine and the CK1δ mutation in mice is the same
mutation that has been identified in a family with inherited migraine with aura. This is consistent
with the finding that CK1δ-T44A mice are more sensitive to CSD and greater cranial arterial
dilation than wildtype animals. This supports the hypothesis that CK1δ contributes to migraine
pathology.
Female CK1δ-T44A animals are more sensitive to thermal stimuli than male CK1δ-T44A
mice before and after injection with 5 mg/kg NTG. This sex difference is consistent with
observations that women are more susceptible to migraine than men61c. Previous studies have
suggested that sex hormones are involved with women having lower pain thresholds and higher
sensitivity to painful stimulations than men70a, 87. This gender difference could be linked to the
sex hormone estrogen, which is modulated by CK1δ38. This gender difference is important since
a significant sex difference is reported in CSD in male and female mice. Female CK1δ and
wildtype mice have a lower threshold for inducing CSD than the male mice of their respective
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genotypes86. A difference in CSD also exists between wildtype and CK1δ-T44A mice, with
CK1δ-T44A mice having a lower threshold to induce CDS than wildtype86. CK1δ-T44A mice
exhibit a gender difference in nociception after NTG injection, which is different from the pain
phenotype expressed in wildtype males and females after NTG injection86. Since CSD models
aura, this could mean that gender might affect occurrence of aura more than nociception. This
represents an important link between estrogen signaling and CK1δ in the migraine pain pathway.
CK1δ regulates estrogen and estrogen is a key difference between males and females.
Estrogen regulates vasodilatation, which modulates pain response57-58. Estrogen acts on estrogen
receptors α and β and CK1δ activates these estrogen receptors. The CK1δ-T44A substitution
likely decreases the phosphorylation level of the estrogen receptors and the different levels of
estrogen present in male and female mice likely have a role in the thermal sensitivity gender
difference exhibited by CK1δ-T44A mice that is absent in wildtype siblings.
We conclude that CK1δ-T44A female mice are more sensitive to thermal stimuli than
wildtype females because of modified CK1δ function. This is important in migraine because the
same CK1δ mutation is identified in a family with inherited migraine with aura. It is also likely
that the sex hormone estrogen is involved in the CK1δ migraine pathway because sex hormones
have been shown to influence sensitivity to painful stimuli70a, 87.
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CHAPTER 3: THE EFFECTS OF ESTROGEN RECEPTOR BETA ON THERMAL
SENSITIVITY

Introduction
Migraine attacks are correlated with changes in estradiol (E2) levels3b, 47a. In women,
migraine onset is most frequent at the dramatic estrogen decline at the beginning of the
menstrual cycle47a. Estrogen regulates inflammation and pain88 and can sensitize pain-sensing
neurons8a. In addition, estradiol can modulate neuronal activity. Synchronous intracellular Ca2+
waves and transients in gonadotrophin-releasing hormone (GnRH), LH releasing, hypocampal,
and cortical neurons are amplified by E2 89. E2 can affect neuronal excitability by modulating
ion channels and receptors
including the coupling of
the α1-adrenergic receptors
to calcium-activated K+
(SK) channels90. These
correlations led us to test
the hypothesis that
estrogen signaling is
important for susceptibility
to migraine.
Transgenic CK1δT44A mice have longer

Figure 9: The length of estrous cycles in hours of wildtype
and CK1δ-T44A mice.

estrous cycles (Figure 9), indicating a relationship between the activity of estrogen and CK1δ
function. As previously established, CKIδ-T44A animals become hypersensitive to some sensory
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stimuli at low doses of NTG and cranial arteries dilate abnormally in CKIδ-T44A mutant
animals in response to CSD86. Estrogen signals through ERß and ER to promote arterial
dilation in response to nitric oxide—a metabolite of NTG 57, 91. CKIδ has been shown to
phosphorylate ER in vitro and decreased CKIδ function reduces ER transcriptional activation,
but increases the levels of ER in cells38. Thus, it could be that the T44A substitution in CKIδ
changes phosphorylation of ER leading to the increased pain responses after NTG injection and
abnormal dilation of cranial arteries with CSD. ERβ is 49% identical and 65% similar to ER,
and ERβ is expressed in the brain. It is unknown if ERβ, like ER, is regulated by CKIδ. If ERβ
is responsible for the pain phenotypes that are downstream of CKIδ in migraine, we would
expect that by reducing function of ERβ in animals that express CKIδ-T44A, they will not
respond faster to heat after low dose NTG injections.

Materials and Methods
Materials: The wildtype mice came from Jackson Labs (Sacramento, CA), the CK1δT44A mice came from the Louis Ptacek lab (UCSF, San Francisco, CA) and the ERβ mice came
from the Jan-Ake Gustafsson lab (Karolinska Institutet, Department of Biosciences and
Nutrition, Sweden). The nitroglycerin (NTG injection, USP 5mg/ml) was from American
Regent, Inc. The saline (0.9% sodium chloride injection, USP) was from Hospir, Inc. The tail
lysis buffer was DirectPCR (Tail) from Viagen. The primers were made in-house on a Mermade
6 (Bioautomation Corporation) DNA synthesizer. The polymerase was GoTaq DNA Polymerase
purchased from Promega. The Hargreaves apparatus was purchased from The University of San
Diego.
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Experimental Animals—All experiments were conducted on C57Bl6 wildtype, CK1δT44A, ERβko/+, or CK1δ-T44A; ERβko/+ mice. All genotypes have a C57Bl6 background and
weighed between 18 and 30 grams during experiments. Animals were acclimated to a 12 hour
light-dark cycle and experiments were performed between 8 a.m. and 2 p.m. at 22°C.
Nitroglycerin Administration—A stock of 5 mg/mL nitroglycerin dissolved in 30%
alcohol, 30% propylene glycol, and water was further diluted fresh each day in 0.9% saline. A
dose of 5 mg/kg NTG was administered Intraperitoneally (IP). Control mice received a dose of
0.9% saline solution.
Hargreaves Assay—Animals were habituated to the testing apparatus for 60 minutes prior
to determination of baseline nociceptive thresholds. To determine thermal nociceptive
thresholds, the Hargreaves assay focuses radiant heat on the hind paw of each animal and
measures the time in seconds until the mouse removes the hind paw from the source of heat. The
Hargreaves apparatus has a pressure-sensitive plate that turns off the heat source and stops a
timer when the paw is lifted in response to pain. The cut off valve of 20.48 seconds was set to
prevent tissue injury. This timer is accurate to one hundredth of a second. Radiant heat intensity
was set at 5%. Three determinations were averaged for every time point with at least 1 minute
between each trial. Initial measurements were taken as a baseline reference before injection with
saline or NTG. The mice were then with saline or NTG and measurements were taken post
injection at time 60 and 90 minutes. The assay was performed by a single researcher who was
blind to both dose and genotype.
Genotyping—Mice were weaned at 25 days, ear marked, and tail clipped for genotyping.
A 0.5cm section was clipped from the end of each animal’s tail. Each tail fragment was lysed
overnight at 55°C in tail lysis buffer and 1 mg/ml of proteinase K solution. The proteinase K
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was then inhibited by incubation at 85°C for 45 mins. The crude cell lysate was used in PCR to
identify either CK1δ T44A mutant or ERβ heterozygote mice. To identify CK1δ-T44A; ERβko/+
mice tail lysates were first amplified with CK1δ-T44A identifying primers. Primers
5’ACACAGTCTGCTGACTGCATCTC and CTCAGGTCTTTCAAATTCTCATT were used.
The program used in the Mastercycler ep (Eppendorf) cycler was 94°C for 5’, 94°C for 30”,
60°C for 1’, 72°C for 1:30’, 72°C for 7’ and 4°C hold with 35 cycles. The products were
subjected to electrophoresis on a 1% agarose gel. Lanes with a band at 800 bp show the CK1δT44A genotype and lanes without a band correspond to wildtype animals.
New PCR reactions containing fresh tail lysate from the same animals were then
amplified using ERβko/+ primers identify the second genotype. Primers
ATCAGCCCATGGGCAGAGTGTG, GTGGATGCCTATGATCACTGTGGA, and
CCAGATGCATAATCACTGCAGACG were used. The Mastercycler ep (Eppendorf) cycler
was used running the following program: 94°C for 5’, 94°C for 30”, 56°C for 30”, 72°C for 1’,
72°C for 7’ and 4°C hold with 35 cycles. The products were subjected to electrophoresis on a 1%
agarose gel. A lane with only band at 500bp shows wildtype mice, while a lane with a band at
500bp and 300bp or just 300bp indicate one mutant allele for ERβ.
Statistical Analysis—For each paw of each animal, three paw removal measurements
were taken for every time point (baseline, 60 and 90 minutes after injection). Heat sensitivity
thresholds from each group of mice treated with equivalent doses of NTG or saline were
averaged. Two-tailed student T-TESTS were performed comparing genotype to genotype, saline
to NTG, and baseline to 60 or 90 minutes for all genotypes and genders. p values are given in
the text. Error bars represent SEM. The number of animals tested for each genotype and each
dose of NTG are indicated in the figure legends.
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Results
To determine the effect of reducing the function of ERβ on the mechanism of migraine,
we compared the sensitivity to thermal stimuli as a function of latency to response to a calibrated
heat source of heterozygous ERβ knockout (ERβKO/+) mice and wildtype mice. We used saline
in order to establish a basis for injection stress (Figure 10). In female mice, ERβKO/+ mice are
less sensitive to pain than their wildtype siblings before injection (p= 3.04E-16). At baseline,
ERβKO/+ mice responded with an average of 12.11 ± 0.22 (s) and wildtype mice responded with
an average of 9.64 ± 0.19 (s). Ninety minutes after injection with saline, the latency to response
averages for both ERβKO/+ and wildtype mice decreased significantly (p= 1.60E-12 and p= 2.70E12

, respectively), but were not different from each other (p=0.42). ERβKO/+ mice had an average

paw withdrawal of 7.96 ± 0.38 (s) at 90 minutes after saline injection and the wildtype mice
responded with an average of 7.66 ± 0.20 (s) at 90 minutes after saline injection.
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Figure 10: The paw-withdrawal response averages to thermal stimuli of female ERβKO/+ and wildtype
mice at baseline and 90 minutes post saline injection. ERβKO/+ n=20 and wildtype n=26.

37

To determine the effect NTG has on thermal sensitivity of ERβKO/+ mice, female
ERβKO/+ and wildtype mice were both injected with 5 mg/kg NTG (Figure 11). At baseline,
ERβKO/+ mice responded with an average of 12.11 ± 0.22 (s) and wildtype mice responded with
an average of 9.64 ± 0.19 (s). The latency to response 90 minutes after 5 mg/kg NTG injection
for ERβKO/+ mice decreased significantly from baseline response (p=4.08E-29), while the
response of wildtype mice at 90 minutes post injection was not different from the response at
baseline (p=0.13). ERβKO/+ mice responded faster than the wildtype mice 90 minutes after NTG
injection (p=0.04). ERβKO/+ mice had an average paw withdrawal response of 8.10 ± 0.25 (s),
while wildtype mice responded in an average of 9.02 ± 0.37 (s).
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Figure 11: The paw-withdrawal response averages to thermal stimuli of female ERβKO/+ and wildtype
mice at baseline and 90 minutes post 5 mg/kg NTG injection. ERβKO/+ n= 21 and wildtype n=26.

To determine if only female ERβKO/+ mice responded differently from wildtype mice to
thermal stimuli, male ERβKO/+ and wildtype mice were injected with saline and 5 mg/kg NTG.
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To establish a control for general stress of injection, ERβKO/+ and wildtype males were injected
with saline (Figure 12). At baseline, male ERβKO/+ responded much slower to thermal stimuli
than wildtype male mice (p=2.41E-7). Male ERβKO/+ mice responded with an average latency to
response of 12.15 ± 0.22 (s), while wildtype mice responded with an average of 10.49 ± 0.22 (s).
However, 90 minutes after saline injection, the previous difference between the ERβKO/+ and
wildtype siblings is no longer present (p=0.25). ERβKO/+ mice had an average paw withdrawal of
9.17 ± 0.25 (s) and wildtype mice had an average paw withdrawal of 8.69 ± 0.27 (s). The initial
difference between the female ERβKO/+ and wildtype animals is again present between the male
ERβKO/+ and wildtype mice, indicating ERβKO/+ decreases sensitivity to thermal stimuli. This
difference is however, nullified by injection stress.
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Figure 12: The paw-withdrawal response averages to thermal stimuli of male ERβKO/+ and wildtype
mice at baseline and 90 minutes post saline injection. ERβKO/+ n=20 and wildtype n=21.
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To compare the effect of NTG on thermal sensitivity of ERβKO/+ mice, ERβKO/+ and
wildtype animals were injected with 5 mg/kg NTG (Figure 13). At baseline, Male ERβKO/+ mice
responded with an average latency to response of 12.15 ± 0.22 (s), while wildtype mice
responded with an average of 10.49 ± 0.22 (s). After 90 minutes post injection, the initial
difference between ERβKO/+ mice and their wildtype siblings is no longer present (p= 0.31).
ERβKO/+ mice had a latency to response average of 9.24 ± 0.31 (s) while wildtype mice had a
response average of 9.27 ± 0.37 (s).
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Figure 13: The paw-withdrawal response averages to thermal stimuli of male ERβKO/+ and wildtype
mice at baseline and 90 minutes post 5 mg/kg NTG injection. ERβKO/+ n= 20 and wildtype n=21.

To determine if ERβ is downstream from CK1δ in the mechanism of migraine, we
performed an epistasis experiment. If ERβ is downstream of CK1δ, then reducing ERβ function
will suppress the CK1δ-T44A phenotype of shorter latency to response to thermal stimuli. This
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means that the CK1δ-T44A; ERβKO/+ mice will have the same phenotype as ERβ. To determine
the effect of CK1δ-T44A on ERβ, the average paw-withdrawal response to thermal stimuli of
CK1δ-T44A; ERβKO/+ animals was compared to the response times of wildtype, CK1δ-T44A,
and ERβKO/+ siblings (Figure 14). At baseline, female CK1δ-T44A: ERβKO/+ mice had a longer
latency to response than wildtype siblings (p= 7.26E-9). CK1δ-T44A; ERβKO/+ mice responded
at baseline with an average of 11.58 ± 0.28 (s), while wildtype mice responded with
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Figure 14: The paw-withdrawal response averages to thermal stimuli of female wildtype, CK1δ-T44A,
ERβKO/+ and CK1δ-T44A; ERβKO/+ mice at baseline and 90 minutes post saline injection.
Wildtype n=26, CK1δ-T44A n=13, ERβKO/+ n=20 and CK1δ-T44A; ERβKO/+ n=12.

an average of 9.64 ± 0.19 (s). CK1δ-T44A; ERβKO/+ mice also responded with a longer latency
response than CK1δ-T44A mice at baseline (p= 8.37E-5). CK1δ-T44A; ERβKO/+ responded to
heat in 11.58 ± 0.28 (s) and the CK1δ-T44A mice responded in 10.01 ± 0.32 (s). However,
CK1δ-T44A; ERβKO/+ animals did not respond differently than ERβKO/+ mice (p= 0.14), which
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responded in 12.11 ± 0.22 (s). This result indicates the CK1δ-T44A mutation does not affect the
initial decrease in sensitivity to thermal stimuli caused by reducing ERβ function that is present
at baseline. To determine the effect of injection stress on thermal sensitivity, all four genotypes
of animals were injected with saline (Figure 14). Wildtype mice responded to heat in 7.66 ±
0.20(s), CK1δ-T44A mice responded in 7.59 ± 0.28 (s), ERβKO/+ mice responded in 7.96 ± 0.38
(s), and CK1δ-T44A; ERβKO/+ mice responded in 7.23 ± 0.44 (s). After injection with saline, all
genotypes experienced a significant increase in sensitivity to thermal stimuli, however there was
no difference between any of the genotypes.
To determine if NTG affects the sensitivity to thermal stimuli of ERβKO/+ and CK1δT44A; ERβKO/+ mice compared to wildtype and CK1δ-T44A mice, all mice were injected
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Figure 15: The paw-withdrawal response averages to thermal stimuli of female wildtype, CK1δ-T44A, ERβKO/+
and CK1δ-T44A; ERβKO/+ mice at baseline and 90 minutes post 5 mg/kg NTG injection. Wildtype n= 26,
CK1δ-T44A n= 14, ERβKO/+ n= 21 and CK1δ-T44A; ERβKO/+ n=12.
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with 5 mg/kg NTG (Figure 15). At baseline, wildtype mice responded to heat in 9.64 ± 0.19 (s),
CK1δ-T44A mice responded in 10.01 ± 0.32 (s), ERβKO/+ mice responded in 12.11 ± 0.22 (s),
and CK1δ-T44A; ERβKO/+ mice responded in 11.58 ± 0.28 (s). At 90 minutes post NTG
injection, CK1δ-T44A mice responded quicker than ERβKO/+ mice (p= 0.03). Transgenic CK1δT44A mice responded with an average of 6.95 ± 0.42 (s) and ERβKO/+ mice responded with an
average of 8.10 ± 0.25 (s). However, at 90 minutes after 5 mg/kg NTG injection, CK1δ-T44A
mice which respond in 6.95 ± 0.42 (s), do not respond significantly differently from CK1δT44A; ERβKO/+ which have an average of 7.68± 0.31 (s) (p= 0.17).

Discussion
A recent study shows that female ERβKO/+ mice have decreased nociception responses
compared to wildtype siblings after acute activation afferent neuron nociceptors, but that male
ERβKO/+ mice do not92. Our data indicate that both male and female ERβKO/+ mice are less
sensitive to thermal stimuli from a calibrated heat source than wildtype mice at baseline, before
injection. This data suggests ERβ is necessary for thermal nociception. Estrogen signaling in
pain is complex, but some studies show high levels of estrogen result in increased pain
sensitivity73, 74, 75. Estrogen alters gene transcription in the trigeminal ganglion, increasing
capsaicin-evoked inward currents, calcium influx, and immunoreactive calcitonin gene-related
peptides, which increase pain behavior93. By reducing ERβ function, the affect of estrogen in
pain modulation is decreased, resulting in decreased pain sensitivity.
At baseline, both male and female wildtype and CK1δ-T44A mice respond to thermal
stimuli similarly. CK1δ-T44A; ERβKO/+ mice are less sensitive to thermal stimuli at baseline
suggesting that reducing the function of ERβ decreases animal sensitivity to thermal stimuli
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regardless of CK1δ function. If CK1δ function is important to modulation of thermal sensitivity
through ERβ, then we would expect that reducing function of both would increase the ERβKO/+
phenotype. Since ERβ is fully functional in CK1δ-T44A mice and CK1δ-T44A mice have
wildtype thermal sensitivity at baseline, we can conclude that CK1δ-T44A does not modulate
ERβ to affect thermal sensitivity in untreated animals.
Ninety minutes after injection with saline, ERβKO/+ and wildtype mice respond to
thermal stimuli similarly. Saline injection is biologically innocuous, but the injection can cause
stress to the animal and stress can increase nociception94. Though ERβ modulates thermal
nociception in non-stressful conditions, stressful conditions could over-ride the affects of
estrogen signaling and could be regulated by a different mechanism. For instance, thermal
sensory neurons could be activated by the stressful condition regardless of estrogen signaling.
For example, the stress hormone cortisol is implicated in many brain functions such as, the
regulation of neuronal cell birth, differentiation and apoptosis, as well as dendritic arborization
and synaptic function95. Increases in stress raise cortisol levels, and result in increased pain
perception94. Stress activated the neurons of ERβKO/+ and wildtype mice and resulted in
increased hypersensitivity to thermal stimuli possibly because of a another signaling mechanism
like cortisol.
Nitroglycerin (NTG) is broken down into nitric oxide (NO) in the body and activates the
trigeminal nucleus caudalis to increase sensitivity to thermal and mechanical stimuli9a-d.
Migraine patients become sensitive to sensory stimuli at clinical doses of NTG, while people
who are unaffected by migraine do not become more sensitive to sensory stimuli at the same
dose8. When female CK1δ-T44A animals are injected with 5 mg/Kg NTG, they become
hypersensitive to thermal stimuli, while wildtype siblings are not affected by the same dose.
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Ninety minutes after 5 mg/kg NTG, ERβKO/+ mice respond to thermal stimuli like wildtype
mice. This result means that estrogen signaling through ERβ is likely not part of the pathway to
NTG-induced thermal sensitivity. However, these are heterozygous ERβKO/+ animals, so it
could be that one copy of ERβ is sufficient for NTG-induced thermal sensitivity.
While CK1δ-T44A mice respond faster to thermal stimuli than ERβKO/+, 90 minutes after
5 mg/kg NTG, CK1δ-T44A; ERβKO/+ mice do not. However, ERβKO/+ mice are not different
from CK1δ-T44A; ERβKO/+ mice post injection. CK1δ-T44A; ERβKO/+ show a trend toward less
sensitivity to thermal stimuli after 5 mg/kg NTG and CK1δ-T44A mice, though not statistically
different. To draw the conclusion that CK1δ is upstream of ERβ and is acting on ERβ to
modulate the mechanism of migraine, it is likely necessary to completely eliminate ERβ function
in a CK1δ-T44A mutant background (CK1δ-T44A; ERβKO/ ERβKO). These mice then need to be
tested for hypersensitivity to thermal stimuli after NTG injection. If the effect of the CK1δ-T44A
is abolished in these mice, then we can conclude that CK1δ is upstream of ERβ and is acting on
ERβ to modulate the mechanism of migraine.
We show that both male and female ERβKO/+ mice are less sensitive to thermal stimuli
than wildtype mice at baseline. This suggests that ERβ plays an important role in thermal
nociception. However, since there is no difference between ERβKO/+ and wildtype mice after
saline or NTG injection, thermal sensory neurons could be activated by the stressful conditions,
through another pathway, regardless of estrogen signaling. This means that estrogen signaling
through ERβ is likely not part of the pathway to NTG induced thermal sensitivity. However,
these are heterozygous ERβKO/+ animals, so it could be that one copy of ERβ is sufficient for
NTG-induced thermal sensitivity and it is necessary to generate complete ERβKO/ ERβKO mice to
fully eliminate the effect of the CK1δ-T44A on NTG-induced hypersensitivity to heat.
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